Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 9
2012 4
2013 16
2014 9
2015 10
2016 7
2017 4
2018 4
2019 14
2020 8
2021 7
2022 8
2023 13
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Börjesson Sjö L, Fan Y, Jison M, McCrae C, Necander S, Shavit A, Walton C, Merkel PA; MANDARA Study Group. Wechsler ME, et al. N Engl J Med. 2024 Mar 7;390(10):911-921. doi: 10.1056/NEJMoa2311155. Epub 2024 Feb 23. N Engl J Med. 2024. PMID: 38393328 Clinical Trial.
OMERACT Definitions for Ultrasonographic Pathologies and Elementary Lesions of Rheumatic Disorders 15 Years On.
Bruyn GA, Iagnocco A, Naredo E, Balint PV, Gutierrez M, Hammer HB, Collado P, Filippou G, Schmidt WA, Jousse-Joulin S, Mandl P, Conaghan PG, Wakefield RJ, Keen HI, Terslev L, D'Agostino MA; OMERACT Ultrasound Working Group. Bruyn GA, et al. J Rheumatol. 2019 Oct;46(10):1388-1393. doi: 10.3899/jrheum.181095. Epub 2019 Feb 1. J Rheumatol. 2019. PMID: 30709946 Free article.
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, van Daele PLA, Finzel S, Noaiseh G, Elgueta S, Hermann J, McCoy SS, Akpek E, Bookman A, Sopala M, Montecchi-Palmer M, Luo WL, Scheurer C, Hueber W; TWINSS study group. Fisher BA, et al. Among authors: finzel s. Lancet. 2024 Aug 10;404(10452):540-553. doi: 10.1016/S0140-6736(24)01211-X. Epub 2024 Jul 31. Lancet. 2024. PMID: 39096929 Clinical Trial.
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group. Spiera R, et al. Among authors: finzel s. Arthritis Rheumatol. 2023 Sep;75(9):1608-1618. doi: 10.1002/art.42510. Epub 2023 Jun 15. Arthritis Rheumatol. 2023. PMID: 37098795 Free article. Clinical Trial.
Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.
Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, Finzel S, Andreica I, Kofler DM, Weiner SM, Lamprecht P, Schulze-Koops H, App C, Pournara E, Mendelson MH, Sieder C, Maricos M, Thiel J. Venhoff N, et al. Among authors: finzel s. Lancet Rheumatol. 2023 Jun;5(6):e341-e350. doi: 10.1016/S2665-9913(23)00101-7. Lancet Rheumatol. 2023. PMID: 38251601 Clinical Trial.
Editorial: Reproducibility and rigour in rheumatology.
Silva A, Fonseca JE, Finzel S. Silva A, et al. Among authors: finzel s. Front Med (Lausanne). 2024 Mar 28;11:1402043. doi: 10.3389/fmed.2024.1402043. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38606158 Free PMC article. No abstract available.
[Pathogenesis of systemic lupus erythematosus].
Finzel S, Schaffer S, Rizzi M, Voll RE. Finzel S, et al. Z Rheumatol. 2018 Nov;77(9):789-798. doi: 10.1007/s00393-018-0541-3. Z Rheumatol. 2018. PMID: 30291433 Review. German.
[Immunopathogenesis of systemic lupus erythematosus].
Aringer M, Finzel S, Voll RE. Aringer M, et al. Among authors: finzel s. Z Rheumatol. 2024 Feb;83(1):68-76. doi: 10.1007/s00393-022-01214-4. Epub 2022 May 13. Z Rheumatol. 2024. PMID: 35551439 Free PMC article. Review. German.
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Brandt-Jürgens J, Burmester GR, Kellner H, Kiltz U, Kofler DM, Rech J, Mojtahed-Poor S, Jonetzko C, Burkhardt H, Behrens F; MUST Investigator Group. Koehm M, et al. Lancet Rheumatol. 2023 Jan;5(1):e14-e23. doi: 10.1016/S2665-9913(22)00329-0. Lancet Rheumatol. 2023. PMID: 38251504 Clinical Trial.
Development of a new ultrasound scoring system to evaluate glandular inflammation in Sjögren's syndrome: an OMERACT reliability exercise.
Hočevar A, Bruyn GA, Terslev L, De Agustin JJ, MacCarter D, Chrysidis S, Collado P, Dejaco C, Fana V, Filippou G, Finzel S, Gandjbakhch F, Hanova P, Hammenfors D, Hernandez-Diaz C, Iagnocco A, Mortada MA, Inanc N, Naredo E, Ohrndorf S, Perko N, Schmidt WA, Tamborrini G, Tomšič M, Chary-Valckenaere I, Zabotti A, Keen HI, Pineda C, D'Agostino MA, Jousse-Joulin S. Hočevar A, et al. Among authors: finzel s. Rheumatology (Oxford). 2022 Aug 3;61(8):3341-3350. doi: 10.1093/rheumatology/keab876. Rheumatology (Oxford). 2022. PMID: 34849616
98 results